Amgen hands off rights to leprosy, tuberculosis med picked up as part of $13.4B Otezla deal
Amgen scored a big pickup with its acquisition of immunology blockbuster Otezla from Bristol Myers Squibb late last year. But that deal also came with a molecule for tuberculosis and leprosy with significantly less commercial value, and Amgen is ready to wipe its hands clean.
As part of the $13.4 billion deal, Amgen took over what became AMG 634 — a phosphodiesterase type 4 inhibitor currently in Phase II trials that is being investigated for the treatment of both tuberculosis and erythema nodosum leprosum, a complication from leprosy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.